SAREPTA THERAPEUTICS, INC. Available-for-sale Securities, Amortized Cost Basis
SAREPTA THERAPEUTICS, INC. (SRPT) had Available-for-sale Securities, Amortized Cost Basis of $792.85 million as of 2018-09-30, per its 10-Q filed 2018-10-31.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-10-31
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $792.85M.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $949.50M.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $1.05B.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $1.09B.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-09-30 | $792.85M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $949.50M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $1.05B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $1.09B 10-Q · filed 2018-10-31 |
| 2017-06-30 | $300.98M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $390.37M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $317.96M 10-K · filed 2018-03-01 |
| 2016-06-30 | $123.21M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $129.16M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $192.60M 10-K · filed 2017-02-28 |
| 2015-09-30 | $99.91M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $156.91M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $166.24M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $210.44M 10-K · filed 2016-02-25 |
| 2014-09-30 | $236.07M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $279.57M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $225.25M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $256.96M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |